Nuvation Bio Inc.
NUVB
Rank in Stocks
#6935
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise... Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.
Share Price
$4.35
Last synced: 2026-11-09
Market Cap
$1.53B
Change (1 day)
4.57%
Change (1 year)
-12.65%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Nuvation Bio Inc. (NUVB)
Category
Healthcare
EPS for Nuvation Bio Inc. (NUVB)
EPS as of September 2026 TTM: $-0.39
According to Nuvation Bio Inc.'s latest financial reports, its current EPS (TTM) is $-0.39. At the end of 2025 the company had an EPS of $-0.60, an increase over its 2024 EPS of $-2.11.
EPS history for Nuvation Bio Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.39 | -35.00% |
| 2025 | $-0.60 | -71.56% |
| 2024 | $-2.11 | 502.86% |
| 2023 | $-0.35 | -27.08% |
| 2022 | $-0.48 | 9.09% |
| 2021 | $-0.44 | 131.58% |
| 2020 | $-0.19 | 18.75% |
| 2019 | $-0.16 | 2,862.96% |
| 2018 | $-0.01 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -4,115.38% |
US
|
|
| $-7.07 | 1,712.82% |
US
|
|
| $-5.29 | 1,256.41% |
AU
|
|
| $12.88 | -3,402.59% |
BE
|
|
| $21.56 | -5,628.21% |
NL
|
Questions about Nuvation Bio Inc.'s earnings per share (EPS)
What is Nuvation Bio Inc.'s earnings per share (EPS)?
Nuvation Bio Inc.'s earnings per share (EPS) over the last twelve months is $-0.39, as of Sep 2026.
What was Nuvation Bio Inc.'s earnings per share (EPS) in 2025?
In 2025, Nuvation Bio Inc.'s earnings per share (EPS) was $-0.60, compared with $-2.11 in 2024.
How has Nuvation Bio Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Nuvation Bio Inc.'s earnings per share (EPS) was highest in 2020 ($-0.19) and lowest in 2024 ($-2.11).
How does Nuvation Bio Inc.'s earnings per share (EPS) compare with similar companies?
Nuvation Bio Inc.'s earnings per share (EPS) ($-0.39) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.